descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 01 Sep 2021 English Publisher:BMJJournal:BMJ Case Reports, volume 14, page e245289 (eissn: 1757-790X,

Authors: Patrick R Ching; Calvin Lee;

doi: 10.1136/bcr-2021-245289

pmid: 34479903

pmc: PMC8420729

Remdesivir-associated bradycardia

- Summary
- Subjects
- Metrics

Abstract

Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using β-blockers.

Related Organizations

University of Maryland Medical Center Midtown Campus
United States
University of Maryland, Baltimore
United States
University of Maryland Medical System
United States
University of Maryland Medical Center
United States
University of Maryland School of Medicine
United States

Keywords

Adult, Male, Alanine, SARS-CoV-2, Case Report, Antiviral Agents, Adenosine Monophosphate, COVID-19 Drug Treatment, Bradycardia, Humans, Aged

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	14
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%